An epileptic seizure is an alteration that occurs in a person, abruptly and unexpectedly and usually ends quickly, due to abnormal activity, sudden, brief and transient, of the most important cells that make up the brain: neurons.

It is quite common for people to suffer at least one epileptic seizure throughout their lives.

It is estimated that between 2 and 5% of the population will experience an episode of epilepsy at some point; however, this does not imply that it is a patient with epilepsy. According to the International League Against Epilepsy (ILAE), to suffer from epilepsy you must have had more than one seizure. In addition, some people may have more than one seizure caused by high fever, diabetes, other diseases, stress, alcohol or drug use. And that doesn’t mean these people have epilepsy.

Each year more than 20,000 new cases are diagnosed in Spain, and it is one of the most common chronic neurological diseases, becoming the second reason for outpatient neurological consultation after headaches. Despite this, patients with epilepsy today still face a serious stigma arising from ignorance and social discrimination.

When are people most likely to develop epilepsy?

New cases of epilepsy are usually more common among children, especially during the first year of life. The rate gradually decreases to about 10 years of age and then stabilizes. After age 55, the rate of new cases of epilepsy begins to increase, as people develop strokes, brain tumours, or Alzheimer’s disease.

It is important to remember that anyone can develop epilepsy. Epilepsy affects both men and women of all races, ethnicities, and ages.

Leave a Reply

Open chat
Contact with us now
Chat with Anna
¡Hola! 👋🏻
Soy Anna, ¿en qué puedo ayudarte?

The user who fills in the information requested in this form declares to be entitled to do so and is solely responsible for the accuracy and completeness of the data and information entered, expressly exonerating MJN NEUROSERVEIS of any liability that may arise for this entity on the occasion of the information provided through this form.

Yes, I accept

L’usuari que complimenta la informació requerida al present formulari declara estar legitimat per això i es fa responsable exclusiu de la veracitat i integritat de les dades i informació que introdueix, exonerant expressament a MJN NEUROSERVEIS de qualsevol responsabilitat que es pugi generar per aquesta entitat amb ocasió de la informació facilitat a través del present formulari.

Si, accepto

El usuario que cumplimenta la información requerida en el presente formulario declara estar legitimado para ello y se hace responsable exclusivo de la veracidad e integridad de los datos e información que introduce, exonerando expresamente a MJN NEUROSERVEIS de cualquier responsabilidad que pudiera generarse para esta entidad con ocasión de la información facilitada a través del presente formulario.

Sí, acepto

Save the date

The next Saturday 21st of November at 4 pm, you will be able to know first hand our product: mjn-SERAS.
mjn-SERAS is a healthcare product that sends a warning signal when the risk of epileptic seizures is high, to the affected person and their trusted contacts.

Sign up now!

    mjn-SERAS is a medical device with CE marking according to the European Directive 93/42/EEC and the Royal Decree RD. 1591/2009.
    Contraindications: Do not use the product if you suffer from an infection in the ear canal or if you suffer from a skin lesion in the vicinity of the product's area of influence.
    Considerations: This medical product works with an APP only on Android phones. The results tested are 96% sensitivity and 94% specificity.

    Save the date

    El próximo sábado 21 de noviembre a las 4 de la tarde, podrás conocer de primera mano nuestro producto: mjn-SERAS.
    mjn-SERAS es un producto sanitario que lanza una señal de aviso cuando el riesgo de crisis de epilepsia es elevado, a la persona afectada y a sus contactos de confianza.


      mjn-SERAS es un producto sanitario con marcado CE conforme a la Directiva Europea 93/42/EEC y el Real Decreto RD. 1591/2009.
      Contraindicaciones: No usar el producto en caso de padecer una infección en el canal auditivo o en caso de padecer una lesión cutánea en las proximidades del área de influencia del producto.
      Consideraciones: Este producto sanitario funciona con una APP solo en teléfonos Android. Los resultados testeados son 96% de sensibilidad y 94% de especificidad.